arrow
J

Jérôme Alexandre

chu lyon
H指数:29
被引数:3,700

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial

新诊断卵巢癌患者新辅助化疗期间循环核小体的基线值和纵向动力学:来自随机II期CHIVA试验GINECO/GINEGEPS研究的结果

2026-07-010
OAAI
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial

奥拉帕利维持治疗在铂类为基础化疗后的晚期/转移性子宫内膜癌中的应用:GINECO随机IIb期UTOLA试验

2025-08-260
OAAI
Identification of a very-high risk subgroup of localized endometrial carcinoma before surgery using circulating tumor DNA: a proof-of-concept study

术前使用循环肿瘤DNA识别局部子宫内膜癌的高危亚群:一项概念验证研究

2025-05-150
PRE
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
2024-12-141
OAAI
Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA

循环肿瘤DNA在转移性子宫内膜癌预后判断和监测中的验证:GINECO试验UTOLA II期随机研究的附加结果

2024-09-010
PRE
TEDOVA: vaccine OSE2101+/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer

TEDOVA: 疫苗OSE2101 /- pembrolizumab作为铂敏感复发性卵巢癌的维持

2024-08-190
PRE
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients
2024-03-260
PRE
Olaparib vs placebo as maintenance therapy after platinumbased chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
2023-10-014
OA
Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
2023-10-011
OAAI
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

奥希替尼在晚期非小细胞肺癌患者中的暴露-反应分析

2022-09-0117
OAAI
Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers
2022-06-255
OA
Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma
2022-03-2212
OA
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
2021-11-0110
OAAI
Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors
2021-10-267
OAAI